Prognostic and predictive molecular markers in cutaneous malignant melanoma: The first step toward personalized medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 4, 2008, Pages 272-294

  Liu, Suxing ^a   Kirschmeier, Paul ^a   Simon, Jason ^b   Seidel Dugan, Cynthia ^a   Puhlmann, Markus ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Discovery Technology   (Finland)

Author keywords

Biomarkers; Drug response; Melanoma; Pharmacogenomics; Tumor classification

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; B RAF KINASE; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKINE; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MESSENGER RNA; N ACETYLGALACTOSAMINYLTRANSFERASE; PROTEIN BCL 6; PROTEIN KINASE C BETA; PROTEIN S100B; QS 21; STAT1 PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR PAX3; TUMOR ANTIGEN; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN 165;

ADJUVANT THERAPY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISTANT METASTASIS; DNA MICROARRAY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOASSAY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR CELL; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

EID: 67649344306     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569208786733866     Document Type: Review

References (145)

1. Adam, B. L.; Qu, Y.; Davis, J. W.; Ward, M. D.; Clements, M. A.; Cazares, L. H.; Semmes, O. J.; Schellhammer, P. F.; Yasui, Y.; Feng, Z. and Wright, G. L. Jr. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62(13), 3609-3614.
2. Alonso, S. R.; Tracey, L.; Ortiz, P.; Pérez-Gómez, B.; Palacios, J.; Pollán, M.; Linares, J.; Serrano, S.; Sáez-Castillo, A. I.; Sánchez, L.; Pajares, R.; Sánchez-Aguilera, A.; Artiga, M. J.; Piris, M. A. and Rodríguez-Peralto, J. L. (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67 (7), 3450-3460.
3. Anzick, S. L.; Kononen, J.; Walker, R. L.; Azorsa, D. O.; Tanner, M. M.; Guan, X. Y.; Sauter, G.; Kallioniemi, O. P.; Trent, J. M. and Meltzer, P. S. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277(5328), 965-968.
4. Atkins, M. B. (2006) Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer Res. 12(7 Suppl.), 2353s-2358s.
5. Atkins, M. B.; Lotze, M. T.; Dutcher, J. P.; Fisher, R. I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L. and Rosenberg, S. A. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116.
6. Auge, J. M.; Molina, R.; Filella, X.; Bosch, E.; Gonzalez Cao, M.; Puig, S.; Malvehy, J.; Castel, T. and Ballesta, A. M. (2005) S-100beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res. 25(3A), 1779-1782.
7. Balázs, M.; Adám, Z.; Treszl, A.; Bégány, A.; Hunyadi, J. and Adány, R. (2001) Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 46(4), 222-232.
8. Balch, C. M.; Soong, S. J.; Atkins, M. B.; Buzaid, A. C.; Cascinelli, N.; Coit, D. G.; Fleming, I. D.; Gershenwald, J. E.; Houghton, A. Jr.; Kirkwood, J. M.; McMasters, K. M.; Mihm, M. F.; Morton, D. L.; Reintgen, D. S.; Ross, M. I.; Sober, A.; Thompson, J. A. and Thompson, J. F. (2004) An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 54, 131-149.
9. Balch, C. M.; Buzaid, A. C.; Soong, S. J.; Atkins, M. B.; Cascinelli, N.; Coit, D. G.; Fleming, I. D.; Gershenwald, J. E.; Houghton, A. Jr.; Kirkwood, J. M.; McMasters, K. M.; Mihm, M. F.; Morton, D. L.; Reintgen, D. S.; Ross, M. I.; Sober, A.; Thompson, J. A. and Thompson, J. F. (2001) Final version of the american joint committee on cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648.
10. Bastian, B. C.; Olshen, A. B.; LeBoit, P. E. and Pinkel, D. (2003) Classifying melanocytic tumors based on DNA copy number changes. Am. J. Pathol. 163(5), 1765-1770.
11. Beghini, A.; Cairoli, R.; Morra, E. and Larizza, L. (1998) In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells Mol. Dis. 24(2), 262-270.
12. Bernard, K.; Litman, E.; Fitzpatrick, J. L.; Shellman, Y. G.; Argast, G.; Polvinen, K.; Everett, A. D.; Fukasawa, K.; Norris, D. A.; Ahn, N. G. and Resing, K. A. (2003) Functional proteomic analysis of melanoma progression. Cancer Res. 63 (20), 6716-6725.
13. Bittner, M.; Meltzer, P.; Chen, Y.; Jiang, Y.; Seftor, E.; Hendrix, M.; Radmacher, M.; Simon, R.; Yakhini, Z.; Ben-Dor, A.; Sampas, N.; Dougherty, E.; Wang, E.; Marincola, F.; Gooden, C.; Lueders, J.; Glatfelter, A.; Pollock, P.; Carpten, J.; Gillanders, E.; Leja, D.; Dietrich, K.; Beaudry, C.; Berens, M.; Alberts, D. and Sondak, V. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540.
14. Brown, K. M.; Macgregor, S.; Montgomery, G. W.; Craig, D. W.; Zhao, Z. Z.; Lyadurai, K.; Henders, A. K.; Homer, N.; Campbell, M. J.; Stark, M.; Thomas, S.; Schmid, H.; Holland, E. A.; Gillanders, E. M.; Duffy, D. L.; Maskiell, J. A.; Jetann, J.; Ferguson, M.; Stephan, D. A.; Cust, A. E.; Whiteman, D.; Green, A.; Olsson, H.; Puig, S.; Ghiorzo, P.; Hansson, J.; Demenais, F.; Goldstein, A. M.; Gruis, N. A.; Elder, D. E.; Bishop, J. N.; Kefford, R. F.; Giles, G. G.; Armstrong, B. K.; Aitken, J. F.; Hopper, J. L.; Martin, N. G.; Trent, J. M.; Mann, G. J. and Hayward, N. K. (2008) Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40(7), 838-840.
15. Brownbridge, G. G.; Gold, J.; Edward, M. and MacKie, R. M. (2001) Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled - polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br. J. Dermatol. 144(2), 279-287.
16. Büttner, P.; Garbe, C.; Bertz, J.; Burg, G.; d'Hoedt, B.; Drepper, H.; Guggenmoos-Holzmann, I.; Lechner, W.; Lippold, A.; Orfanos, C. E. et al. (1995) Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 75(10), 2499-2506.
17. Carrillo, E.; Prados, J.; Marchal, J. A.; Boulaiz, H.; Martínez, A.; Rodríguez-Serrano, F.; Caba, O.; Serrano, S. and Aránega, A. (2006) Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Dis. Markers 22(3), 175-181.
18. Carta, F.; Demuro, P. P.; Zanini, C.; Santona, A.; Castiglia, D.; D'Atri, S.; Ascierto, P. A.; Napolitano, M.; Cossu, A.; Tadolini, B.; Turrini, F.; Manca, A.; Sini, M. C.; Palmieri, G.; Rozzo, A. C. and Italian Melanoma Intergroup. (2005) Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res. 15(4), 235-244.
19. Certa, U.; Wilhelm-Seiler, M.; Foser, S.; Broger, C. and Neeb, M. (2003) Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha. Gene 315, 79-86.
20. Certa, U.; Seiler, M.; Padovan, E. and Spagnoli, G. C. (2001) High density oligonucleotide array analysis of interferon-alpha2a sensitivity and transcriptional response in melanoma cells. Br. J. Cancer 85(1), 107-114.
21. Chabot, B.; Stephenson, D. A.; Chapman, V. M.; Besmer, P. and Bernstein, A. (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335(6185), 88-89.
22. Chin, L. and Gray, J. W. (2008) Translating insights from the cancer genome into clinical practice. Nature 452(7187), 553-563.
23. Cho, K. H.; Hashimoto, K.; Taniguchi, Y.; Pietruk, T.; Zarbo, R. J. and An, T. (1990) Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66(4), 765-771.
24. Critchley-Thorne, R. J.; Yan, N.; Nacu, S.; Weber, J.; Holmes, S. P. and Lee, P. P. (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 4(5), e176.
25. Cronin, M.; Sangli, C.; Liu, M. L.; Pho, M.; Dutta, D.; Nguyen, A.; Jeong, J.; Wu, J.; Langone, K. C. and Watson, D. (2007) Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53(6), 1084-1091.
26. Curtin, J. A.; Busam, K.; Pinkel, D. and Bastian, B. C. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24(26), 4340-4346.
27. Curtin, J. A.; Fridlyand, J.; Kageshita, T.; Patel, H. N.; Busam, K. J.; Kutzner, H.; Cho, K. H.; Aiba, S.; Brocker, E. B.; LeBoit, P. E.; Pinkel, D. and Bastian, B. C. (2005) Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
28. de Snoo, F. A. and Hayward, N. K. (2005) Cutaneous melanoma susceptibility and progression genes. Cancer Lett. 230(2), 153-186.
29. Deichmann, M.; Benner, A.; Bock, M.; Jäckel, A.; Uhl, K.; Waldmann, V. and Näher, H. (1999) S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 17(6), 1891-1896.
30. Domingo-Domènech, J.; Castel, T.; Auge, J. M.; Garcia-Albeniz, X. A.; Conill, C.; Puig, S.; Vilella, R.; Matas, J.; Malvehy, J.; Gascón, P.; Mellado, B. and Molina, R. (2007) Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 28(5), 264-272.
31. Domingo-Domènech, J.; Molina, R.; Castel, T.; Montagut, C.; Puig, S.; Conill, C.; Martí, R.; Vera, M.; Auge, J. M.; Malvehy, J.; Grau, J. J.; Gascon, P. and Mellado, B. (2005) Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon - comparison with tyrosinase RT-PCR. Oncology 68(4-6), 341-349.
32. Du, Z.; Wei, L.; Murti, A.; Pfeffer, S. R.; Fan, M.; Yang, C. H. and Pfeffer, L. M. (2007) Non-conventional signal transduction by type 1 interferons: The NF-kappaB pathway. J. Cell. Biochem. 102(5), 1087-1094.
33. Duffy, D. L.; Box, N. F.; Chen, W.; Palmer, J. S.; Montgomery, G. W.; James, M. R.; Hayward, N. K.; Martin, N. G. and Sturm, R. A. (2004) Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum. Mol. Genet. 13(4), 447-461.
34. Enk, C. D.; Lotem, M.; Gimon, Z. and Hochberg, M. (2004) Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res. 14(5), 361-365.
35. Eton, O.; Legha, S. S.; Moon, T. E.; Buzaid, A. C.; Papadopoulos, N. E.; Plager, C.; Burgess, A. M.; Bedikian, A. Y.; Ring, S.; Dong, Q.; Glassman, A. B.; Balch, C. M. and Benjamin, R. S. (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16(3), 1103-1111.
36. Falkson, C. I.; Ibrahim, J.; Kirkwood, J. M.; Coates, A. S.; Atkins, M. B. and Blum, R. H. (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 16(5), 1743-1751.
37. Fisher, B.; Redmond, C.; Brown, A.; Fisher, E. R.; Wolmark, N.; Bowman, D.; Plotkin, D.; Wolter, J.; Bornstein, R.; Legault-Poisson, S. and Saffer, E. A. (1986) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 4(4), 459-471.
38. Flaherty, K. T. (2006) Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. 12(7 Suppl.), 2366s-2370s.
39. Fodor, S. P.; Read, J. L.; Pirrung, M. C.; Stryer, L.; Lu, A. T. and Solas, D. (1991) Light-directed, spatially addressable parallel chemical synthesis. Science 251(4995), 767-773.
40. Franzke, A.; Probst-Kepper, M.; Buer, J.; Duensing, S.; Hoffmann, R.; Wittke, F.; Volkenandt, M.; Ganser, A. and Atzpodien, J. (1998) Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br. J. Cancer 78(1), 40-45.
41. Fujimoto, A.; O'Day, S. J.; Taback, B.; Elashoff, D. and Hoon, D. S. (2004) Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 64(12), 4085-4088.
42. Gill, M. and Celebi, J. T. (2005) B-RAF and melanocytic neoplasia. J. Am. Acad. Dermatol. 53(1), 108-114.
43. Glumac, N.; Snoj, M.; Hocevar, M. and Novakovic, S. (2006) Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma. Neoplasma 53(1), 9-14.
44. Glumac, N.; Hocevar, M.; Snoj, M. and Novakovic, S. (2001) Detection of tyrosinase mRNA by an optimised nested RT-PCR in the peripheral blood of patients with advanced malignant melanoma. J. Exp. Clin. Cancer Res. 20(4), 529-536.
45. Gogas, H.; Ioannovich, J.; Dafni, U.' Stavropoulou-Giokas, C.; Frangia, K.; Tsoutsos, D.; Panagiotou, P.; Polyzos, A.; Papadopoulos, O.; Stratigos, A.; Markopoulos, C.; Bafaloukos, D.; Pectasides, D.; Fountzilas, G. and Kirkwood, J. M. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354(7), 709-718.
46. Gogas, H.; Kefala, G.; Bafaloukos, D.; Frangia, K.; Polyzos, A.; Pectasides, D.; Tsoutsos, D.; Panagiotou, P.; Ioannovich, J. and Loukopoulos, D. (2002) Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 87(2), 181-186.
47. Goldstein, A. M.; Landi, M. T.; Tsang, S.; Fraser, M. C.; Munroe, D. J. and Tucker, M. A. (2005) Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol. Biomarkers Prev. 14(9), 2208-2212.
48. Greene, F. L.; Page, D. L.; Fleming, I. D.; Fritz, A. G.; Balch, C. M.; Haller, D. G. and Morrow, M. (2002) AJCC cancer staging manual, Springer-Verlag, New York, NY, pp 229-254.
49. Hamberg, A. P.; Korse, C. M.; Bonfrer, J. M. and de Gast, G. C. (2003) Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 13(1), 45-49.
50. Hanash, S. M.; Pitteri, S. J. and Faca, V. M. (2008) Mining the plasma proteome for cancer biomarkers. Nature 452(7187), 571-579.
51. Haqq, C.; Nosrati, M.; Sudilovsky, D.; Crothers, J.; Khodabakhsh, D.; Pulliam, B. L.; Federman, S.; Miller, J. R. 3rd; Allen, R. E.; Singer, M. I.; Leong, S. P.; Ljung, B. M.; Sagebiel, R. W. and Kashani-Sabet, M. (2005) The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. USA 102(17), 6092-6097.
52. Hauschild, A.; Engel, G.; Brenner, W.; Gläser, R.; Mönig, H.; Henze, E. and Christophers, E. (1999) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/ or immunotherapy. Br. J. Dermatol. 140(6), 1065-1071.
53. Hill, G. J. 2nd.; Krementz, E. T. and Hill, H. Z. (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53(6), 1299-1305.
54. Höglund, M.; Gisselsson, D.; Hansen, G. B.; White, V. A.; Säll, T.; Mitelman, F. and Horsman, D. (2004) Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution. Int. J. Cancer 108(1), 57-65.
55. Isozaki, K.; Terris, B.; Belghiti, J.; Schiffmann, S.; Hirota, S. and Vanderwinden, J. M. (2000) Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am. J. Pathol. 157(5), 1581-1585.
56. Ito, N.; Eto, M.; Nakamura, E.; Takahashi, A.; Tsukamoto, T.; Toma, H.; Nakazawa, H.; Hirao, Y.; Uemura, H.; Kagawa, S.; Kanayama, H.; Nose, Y.; Kinukawa, N.; Nakamura, T.; Jinnai, N.; Seki, T.; Takamatsu, M.; Masui, Y.; Naito, S. and Ogawa, O. (2007) STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25(19), 2785-2791.
57. Jackson, D. P.; Watling, D.; Rogers, N. C.; Banks, R. E.; Kerr, I. M.; Selby, P. J. and Patel, P. M. (2003) The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res. 13(3), 219-229.
58. Jaeger, J.; Koczan, D.; Thiesen, H. J.; Ibrahim, S. M.; Gross, G.; Spang, R. and Kunz, M. (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 13(3), 806-815.
59. Jönsson, G.; Dahl, C.; Staaf, J.; Sandberg, T.; Bendahl, P. O.; Ringnér, M.; Guldberg, P. and Borg, A. (2007) Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26(32), 4738-4748.
60. Jury, C. S.; McAllister, E. J. and MacKie, R. M. (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol. 143(2), 269-274.
61. Keilholz, U.; Goldin-Lang, P.; Bechrakis, N. E.; Max, N.; Letsch, A.; Schmittel, A.; Scheibenbogen, C.; Heufelder, K.; Eggermont, A. and Thiel, E. (2004) Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin. Cancer Res. 10(5), 1605-1612.
62. Kelley, M. C.; Gupta, R. K.; Hsueh, E. C.; Yee, R.; Stern, S. and Morton, D. L. (2001) Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J. Clin. Oncol. 19(4), 1176-1182.
63. Kelley, M. C.; Jones, R. C.; Gupta, R. K.; Yee, R.; Stern, S.; Wanek, L. and Morton, D. L. (1998) Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer 83(7), 1355-1361.
64. Kim, S. H.; Cohen, B.; Novick, D. and Rubinstein, M. (1997) Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene 196(1-2), 279-286.
65. Kirkwood, J. M. (1998) Systemic adjuvant treatment of high-risk melanoma: The role of interferon alfa-2b and other immunotherapies. Eur. J. Cancer 34(Suppl. 3), S12-S17.
66. Kirkwood, J. M.; Ibrahim, J. G.; Sosman, J. A.; Sondak, V. K.; Agarwala, S. S.; Ernstoff, M. S. and Rao, U. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380.
67. Kirkwood, J. M.; Strawderman, M. H.; Ernstoff, M. S.; Smith, T. J.; Borden, E. C. and Blum, R. H. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17.
68. Kounalakis, N. and Goydos, J. S. (2005) Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management. Curr. Oncol. Rep. 7(5), 377-382.
69. Koyanagi, K.; Kuo, C.; Nakagawa, T.; Mori, T.; Ueno, H.; Lorico, A. R. Jr.; Wang, H. J.; Hseuh, E.; O'Day, S. J. and Hoon, D. S. (2005a) Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: Relation to disease stage in melanoma patients. Clin. Chem. 51(6), 981-988.
70. Koyanagi, K.; O'Day, S. J.; Gonzalez, R.; Lewis, K.; Robinson, W. A.; Amatruda, T. T.; Kuo, C.; Wang, H. J.; Milford, R.; Morton, D. L. and Hoon, D. S. (2006) Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin. Cancer Res. 12(4), 1137-1143.
71. Koyanagi, K.; O'Day, S. J.; Gonzalez, R.; Lewis, K.; Robinson, W. A.; Amatruda, T. T.; Wang, H. J.; Elashoff, R. M.; Takeuchi, H.; Umetani, N. and Hoon, D. S. (2005b) Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: Outcome prediction in a multicenter trial. J. Clin. Oncol. 23(31), 8057-8064.
72. Koynova, D. K.; Jordanova, E. S.; Milev, A. D.; Dijkman, R.; Kirov, K. S.; Toncheva, D. I. and Gruis, N. A. (2007) Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma. Melanoma Res. 17(1), 37-41.
73. Krähn, G; Kaskel, P.; Sander, S.; Waizenhöfer, P. J.; Wortmann, S.; Leiter, U. and Peter, R. U. (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 21(2B), 1311-1316.
74. Krepler, C.; Certa, U.; Wacheck, V.; Jansen, B.; Wolff, K. and Pehamberger, H. (2004) Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma scid mouse xenotransplantation model. J. Invest. Dermatol. 123(4), 664-669.
75. Kwon, B. S.; Haq, A. K.; Pomerantz, S. H. and Halaban, R. (1987) Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc. Natl. Acad. Sci. USA 84(21), 7473-7477.
76. Lee, S. C.; Sim, N.; Clement, M. V.; Yadav, S. K. and Pervaiz, S. (2007) Dominant negative RAC1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27: A functional proteomic analysis. Proteomics 7(22), 4112-4122.
77. Lesinski, G. B.; Valentino, D.; Hade, E. M.; Jones, S.; Magro, C.; Chaudhury, A. R.; Walker, M. J. and Carson, W. E. 3rd. (2005) Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol. Immunother. 54(9), 815-825.
78. Li, J.; Zhang, Z.; Rosenzweig, J.; Wang, Y. Y. and Chan, D. W. (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48(8), 1296-1304.
79. Liu, D.; O'Day, S. J.; Yang, D.; Boasberg, P.; Milford, R.; Kristedja, T.; Groshen, S. and Weber, J. (2005) Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: An exploratory study. Clin. Cancer Res. 11(3), 1237-1246.
80. Lotze, M. T.; Matory, Y. L.; Rayner, A. A.; Ettinghausen, S. E.; Vetto, J. T.; Seipp, C. A. and Rosenberg, S. A. (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58(12), 2764-2772.
81. Ma, X. J.; Salunga, R.; Dahiya, S.; Wang, W.; Carney, E.; Durbecq, V.; Harris, A.; Goss, P.; Sotiriou, C.; Erlander, M. and Sgroi, D. (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14(9), 2601-2608.
82. Ma, X. J.; Hilsenbeck, S. G.; Wang, W.; Ding, L.; Sgroi, D. C.; Bender, R. A.; Osborne, C. K.; Allred, D. C. and Erlander, M. G. (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol. 24(28), 4611-4619.
83. Maldonado, J. L.; Fridlyand, J.; Patel, H.; Jain, A. N.; Busam, K.; Kageshita, T.; Ono, T.; Albertson, D. G.; Pinkel, D. and Bastian, B. C. (2003) Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 95(24), 1878-1890.
84. Margolin, K. A. (2004) Biochemotherapy for melanoma: Rational therapeutics in the search for weapons of melanoma destruction. Cancer 101(3), 435-438.
85. Marks, A.; Petsche, D.; O'Hanlon, D.; Kwong, P. C.; Stead, R.; Dunn, R.; Baumal, R. and Liao, S. K. (1990) S100 protein expression in human melanoma cells: Comparison of levels of expression among different cell lines and individual cells in different phases of the cell cycle. Exp. Cell. Res. 187(1), 59-64.
86. Mårtenson, E. D.; Hansson, L. O.; Nilsson, B.; von Schoultz, E.; Månsson Brahme, E.; Ringborg, U. and Hansson, J. (2001) Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 19(3), 824-831.
87. Mellado, B.; Del Carmen Vela, M.; Colomer, D.; Gutierrez, L.; Castel, T.; Quintó, L.; Fontanillas, M.; Reguart, N.; Domingo-Domènech, J. M.; Montagut, C.; Estapé, J. and Gascón, P. (2002) Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol. 20(19), 4032-4039.
88. Mellado, B.; Gutierrez, L.; Castel, T.; Colomer, D.; Fontanillas, M.; Castro, J. and Estapé, J. (1999) Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin. Cancer Res. 5(7), 1843-1848.
89. Mian, S.; Ugurel, S.; Parkinson, E.; Schlenzka, I.; Dryden, I.; Lancashire, L.; Ball, G.; Creaser, C.; Rees, R. and Schadendorf, D. (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 23(22), 5088-5093.
90. Moore, S. R.; Persons, D. L.; Sosman, J. A.; Bobadilla, D.; Bedell, V.; Smith, D. D.; Wolman, S. R.; Tuthill, R. J.; Moon, J.; Sondak., V. K. and Slovak, M. L. (2008) Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: A Southwest Oncology Group Study (S9431). Clin. Cancer Res. 14(10), 2927-2935.
91. Mori, T.; O'Day, S. J.; Umetani, N.; Martinez, S. R.; Kitago, M.; Koyanagi, K.; Kuo, C.; Takeshima, T. L.; Milford, R.; Wang, H. J.; Vu, V. D.; Nguyen, S. L. and Hoon, D. S. (2005) Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 23(36), 9351-9358.
92. Moschos, S. J.; Edington, H. D.; Land, S. R.; Rao, U. N.; Jukic, D.; Shipe-Spotloe, J. and Kirkwood, J. M. (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol. 24(19), 3164-3171.
93. Namiki, T.; Yanagawa, S.; Izumo, T.; Ishikawa, M.; Tachibana, M.; Kawakami, Y.; Yokozeki, H.; Nishioka, K. and Kaneko, Y. (2005) Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet. Cytogenet. 157(1), 1-11.
94. O'Day, S. J.; Kim, C. J. and Reintgen, D. S. (2002) Metastatic melanoma: Chemotherapy to biochemotherapy. Cancer Control 9(1), 31-38.
95. Osella-Abate, S.; Savoia, P.; Quaglino, P.; Fierro, M. T.; Leporati, C.; Ortoncelli, M. and Bernengo, M. G. (2003) Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: A clinical follow-up study of 110 patients. Br. J. Cancer 89(8), 1457-1462.
96. Osella-Abate, S.; Quaglino, P.; Savoia, P.; Leporati, C.; Comessatti, A. and Bernengo, M. G. (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: Correlation with the clinical course. Melanoma Res. 12(4), 325-334.
97. Palmer, J. S.; Duffy, D. L.; Box, N. F.; Aitken, J. F.; O'Gorman, L. E.; Green, A. C.; Hayward, N. K.; Martin, N. G. and Sturm, R. A. (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype? Am. J. Hum. Genet. 66(1), 176-186.
98. Palmieri, G.; Ascierto, P. A.; Perrone, F.; Satriano, S. M.; Ottaiano, A.; Daponte, A.; Napolitano, M.; Caracò, C.; Mozzillo, N.; Melucci, M. T.; Cossu, A.; Tanda, F.; Gallo, C.; Satriano, R. A. and Castello, G. (2003) Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 21(5), 767-773.
99. Paterlini-Brechot, P. and Benali, N. L. (2007) Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett. 253(2), 180-204.
100. Perez, E. A. and Baweja, M. (2008) HER2-positive breast cancer: Current treatment strategies. Cancer Invest. 26(6), 545-552.
101. Perou, C. M.; Sørlie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lønning, P. E.; Børresen-Dale, A. L.; Brown, P. O. and Botstein, D. (2000) Molecular portraits of human breast tumours. Nature 406(6797), 747-752.
102. Potti, A.; Mukherjee, S.; Petersen, R.; Dressman, H. K.; Bild, A.; Koontz, J.; Kratzke, R.; Watson,. M. A.; Kelley,. M.; Ginsburg, G. S.; West, M.; Harpole, D. H. Jr. and Nevins, J. R. (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355(6), 570-580.
103. Quaglino, P.; Osella-Abate, S.; Cappello, N.; Ortoncelli, M.; Nardò, T.; Fierro, M. T.; Cavallo, F.; Savoia, P. and Bernengo, M. G. (2007) Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res. 17(2), 75-82.
104. Ramani, P. and Balkwill, F. R. (1988) Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice. Br. J. Cancer 58(3), 350-354.
105. Ramaswamy, S.; Ross, K. N.; Lander, E. S. and Golub, T. R. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33(1), 49-54.
106. Rangel, J.; Torabian, S.; Shaikh, L.; Nosrati, M.; Baehner, F. L.; Haqq, C.; Leong, S. P.; Miller, J. R. 3rd; Sagebiel. R. W. and Kashani-Sabet. M. (2006) Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J. Clin. Oncol. 24(28), 4565-4569.
107. Rimm, D. L.; Camp, R. L.; Charette, L. A.; Costa, J.; Olsen, D. A. and Reiss, M. (2001) Tissue microarray: A new technology for amplification of tissue resources. Cancer J. 7(1), 24-31.
108. Rosenberg, S. A.; Yang, J. C.; White, D. E. and Steinberg, S. M. (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann. Surg. 228(3), 307-319.
109. Ross, A. A.; Cooper, B. W.; Lazarus, H. M.; Mackay, W.; Moss, T. J.; Ciobanu, N.; Tallman, M. S.; Kennedy, M. J.; Davidson, N. E.; Sweet, D.; Winter, C.; Akard, L.; Jansen, J.; Copelan, E.; Meagher, R. C.; Herzig, R. H.; Klumpp, T. R.; Kahn, D. G. and Warner, N. E. (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82(9), 2605-2610.
110. Ross, J. S.; Hatzis, C.; Symmans, W. F.; Pusztai, L. and Hortobágyi, G. N. (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13(5), 477-493.
111. Rote, N. S.; Gupta, R. K. and Morton, D. L. (1980) Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms. J. Surg. Res. 29(1), 18-22.
112. Sassano, A.; Verma, A. and Platanias, L. C. (2005) Mitogen-activated protein kinase pathways in interferon signaling. Methods Mol. Med. 116, 135-150.
113. Schena, M.; Shalon, D.; Davis, R. W. and Brown, P. O. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470.
114. Schmidt, H.; Johansen, J. S.; Gehl, J.; Geertsen, P. F.; Fode, K. and von der Maase, H. (2006a) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5), 1130-1139.
115. Schmidt, H.; Johansen, J. S.; Sjoegren, P.; Christensen, I. J.; Sorensen, B. S.; Fode, K.; Larsen, J. and von der Maase, H. (2006b) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J. Clin. Oncol. 24(5), 798-804.
116. Schmidt, H.; Sorensen, B. S.; Fode, K.; Nexo, E. and von der Maase, H. (2005) Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 15(5), 409-416.
117. Schmidt, H.; Sorensen, B. S.; Nexo, E. and von der Maase, H. (2004) S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. Melanoma Res. 14(3), 211-215.
118. Shinozaki, M.; O'Day, S. J.; Kitago, M.; Amersi, F.; Kuo, C.; Kim, J.; Wang, H. J and Hoon, D. S. (2007) Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin. Cancer Res. 13(7), 2068-2074.
119. Sirott, M. N.; Bajorin, D. F.; Wong, G. Y.; Tao, Y.; Chapman, P. B.; Templeton, M. A. and Houghton, A. N. (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10), 3091-3098.
120. Smit, L. H.; Korse, C. M.; Hart, A. A.; Bonfrer, J. M.; Haanen, J. B.; Kerst, J. M.; Nieweg, O. E. and de Gast, G. C. (2005) Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur. J. Cancer 41(3), 386-392.
121. Smith, B.; Selby, P.; Southgate, J.; Pittman, K.; Bradley, C. and Blair, G. E. (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338(8777), 1227-1229.
122. Sørlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lønning, P. and Børresen-Dale, A. L. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98(19), 10869-10874.
123. Sørlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; Brown, P. O.; Børresen-Dale, A. L. and Botstein, D. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100(14), 8418-8423.
124. Sosa, M. S.; Girotti, M. R.; Salvatierra, E.; Prada, F.; de Olmo, J. A.; Gallango, S. J.; Albar, J. P.; Podhajcer, O. L. and Llera, A. S. (2007) Proteomic analysis identified n-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 7(22), 4123-4134.
125. Sotiriou, C.; Neo, S. Y.; McShane, L. M.; Korn, E. L.; Long, P. M.; Jazaeri, A.; Martiat, P.; Fox, S. B.; Harris, A. L. and Liu, E. T. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 100(18), 10393-10398.
126. Stark, M. and Hayward, N. (2007) Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67(6), 2632-2642.
127. Stockwin, L. H.; Blonder, J.; Bumke, M. A.; Lucas, D. A.; Chan, K. C.; Conrads, T. P.; Issaq, H. J.; Veenstra, T. D.; Newton, D. L. and Rybak, S. M. (2006) Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J. Proteome Res. 5(11), 2996-3007.
128. Strobel, K.; Skalsky, J.; Kalff, V.; Baumann, K.; Seifert, B.; Joller-Jemelka, H.; Dummer, R. and Steinert, H. C. (2007) Tumour assessment in advanced melanoma: Value of FDG-PET/CT in patients with elevated serum S-100B. Eur. J. Nucl. Med. Mol. Imaging 34(9), 1366-1375.
129. Taback, B.; O'Day, S. J.; Boasberg, P. D.; Shu, S.; Fournier, P.; Elashoff, R.; Wang, H. J. and Hoon, D. S. (2004) Circulating DNA microsatellites: Molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J. Natl. Cancer Inst. 96(2), 152-156.
130. Tanami, H.; Imoto, I.; Hirasawa, A.; Yuki, Y.; Sonoda, I.; Inoue, J.; Yasui, K.; Misawa-Furihata, A.; Kawakami, Y. and Inazawa, J. (2004) Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23(54), 8796-9804.
131. Thomas, N. E. (2006) BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res. 16(2).
132. van 't Veer, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der Kooy, K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R. and Friend, S. H. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536.
133. Verma, A. and Platanias, L. C. (2002) Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. Leuk. Lymphoma 43(4), 703-709.
134. Vial, T. and Descotes, J. (1994) Clinical toxicity of the interferons. Drug Saf. 10(2), 115-150.
135. Visús, C.; Andres, R.; Mayordomo, J. I.; Martinez-Lorenzo, M. J.; Murillo, L.; Sáez-Gutiérrez, B.; Diestre, C.; Marcos, I.; Astier, P.; Godino, J.; Carapeto-Marquez de Prado, F. J.; Larrad, L. and Tres, A. (2007) Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res. 17(2), 83-89.
136. Voit, C.; Kron, M.; Rademaker, J.; Schwürzer-Voit, M.; Sterry, W.; Weber, L.; Ozdemir, C.; Proebstle, T. and Keilholz, U. (2005) Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J. Clin. Oncol. 23(6), 1218-1227.
137. Weissleder, R. and Pittet, M. J. (2008) Imaging in the era of molecular oncology. Nature 452(7187), 580-589.
138. Whiteman, D. C.; Whiteman, C. A. and Green, A. C. (2001) Childhood sun exposure as a risk factor for melanoma: A systematic review of epidemiologic studies. Cancer Causes Control 12(1), 69-82.
139. Winnepenninckx, V.; Lazar, V.; Michiels, S.; Dessen, P.; Stas, M.; Alonso, S. R.; Avril, M. F.; Ortiz Romero, P. L.; Robert, T.; Balacescu, O.; Eggermont, A. M.; Lenoir, G.; Sarasin, A.; Tursz, T.; van den Oord, J. J. and Spatz, A. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl. Cancer Inst. 98(7), 472-482.
140. Xi, L.; Nicastri, D. G.; El-Hefnawy, T.; Hughes, S. J.; Luketich, J. D. and Godfrey, T. E. (2007) Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin. Chem. 53(7), 1206-1215.
141. Yang, C. H.; Murti, A.; Valentine, W. J.; Du, Z. and Pfeffer, L. M. (2005) Interferon alpha activates NF-kappaB in JAK1-deficient cells through a TYK2-dependent pathway. J. Biol. Chem. 280(27), 25849-25853.
142. Yurkovetsky, Z. R.; Kirkwood, J. M.; Edington, H. D.; Marrangoni, A. M.; Velikokhatnaya, L.; Winans, M. T.; Gorelik, E. and Lokshin, A. E. (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin. Cancer Res. 13(8), 2422-2428.
143. Zhang, Z.; Bast, R. C. Jr.; Yu, Y.; Li, J.; Sokoll, L. J.; Rai, A. J.; Rosenzweig, J. M.; Cameron, B.; Wang, Y. Y.; Meng, X. Y.; Berchuck, A.; Van Haaften-Day, C.; Hacker, N. F.; de Bruijn, H. W.; van der Zee, A. G.; Jacobs, I. J.; Fung, E. T. and Chan, D. W. (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890.
144. Zhao, C.; Yasui, K.; Lee, C. J.; Kurioka, H.; Hosokawa, Y.; Oka, T. and Inazawa, J. (2003) Elevated expression levels of ncoa3, top1, and tfap2c in breast tumors as predictors of poor prognosis. Cancer 98(1), 18-23.
145. Zwierzina, H. (2008) Biomarkers in drug development. Ann. Oncol. 19 (Suppl. 5), v33-37.